Rheumatoid arthritis: current concepts and management, Part 2

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder primarily affecting joints.
• Initial management often includes conservative non-drug therapies and nonsteroidal anti-inflammatory drugs (NSAIDs).

Observation:

• For patients with progressive or unresponsive disease, slow-acting antirheumatic drugs (SAARDs) are indicated.
• SAARDs carry significant and frequent adverse effects, necessitating careful risk-benefit assessment.
• Established SAARDs include gold compounds, antimalarials, and penicillamine, with sulfasalazine emerging for early RA.
• Methotrexate is FDA-approved for RA, considered after initial therapies fail.
• Cytotoxic agents like azathioprine and cyclophosphamide are reserved for severe RA due to malignancy risks.
• Potent agents such as chlorambucil and cyclosporin A are options for refractory RA.
• Corticosteroids are used short-term as adjunctive or intra-articular therapy for refractory cases.

Findings:

• The choice of SAARD depends on the individual patient's risk-to-benefit profile.
• The optimal timing for initiating SAARDs (early RA) and their combination use remains a subject of controversy.

Implications:

• Understanding the spectrum of RA therapies, from conservative measures to potent immunosuppressants, is crucial for effective patient management.
• Careful consideration of drug toxicity and efficacy is paramount in tailoring treatment strategies for rheumatoid arthritis.
• Further research may clarify the controversial aspects of early and combination SAARD therapy in RA.